Emergent BioSolutions Reports Financial Results For First Quarter 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/28/2026
- S&P 500 ends higher as investors await tech earnings
- NVIDIA’s rising CDS the talk of Wall Street amid circular financing fears
- Market watchers weigh chances of a surprise Fed rate hike tomorrow
- U.S. chip stocks extend losses on AI financing, China competition fears
- Tesla to buy power from Arizona solar project
- Visa (V) To Cut 7% Of Its Workforce, Totaling About 2,600 Jobs - Bloomberg
- BTIG Upgrades Outlook Therapeutics Inc. (OTLK) to Buy
- ASML and U.S. chip stocks sink on report of China’s DUV breakthrough
- Carpenter Technology CEO Brian Malloy passes; Tony Thene returns as CEO
- Applied Digital (APLD) Tops Q4 EPS by 23c, Revenue Beats
Emergent BioSolutions (EBS) Tops Q1 EPS by 6c
April 28, 2022 4:36 PM EDTEmergent BioSolutions (NYSE: EBS) reported Q1 EPS of $0.18, $0.06 better than the analyst estimate of $0.12. Revenue for the quarter came in at $307.5 million versus the consensus estimate of $283.57 million.
For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.
... More